HK Stock Market Move | Long-acting anti-TSLP antibody phase II clinical trial completes first dosing, HBM HOLDINGS-B(02142) and SKB BIO(06990) both rose more than 5% in intraday trading.

HBM HOLDINGS-B (02142) and SKB BIO (06990) both saw gains against the market today. As of press time, HBM Pharmaceuticals rose by 3.46% to HK$9.86, while SKB BIO rose by 3.82% to HK$402.2. On the news front, on June 9th, KOLON Life Science announced that a phase II clinical trial led by its partner Windward Bio has completed dosing the first group of patients. The study aims to evaluate the efficacy and safety of SKB378/WIN378 (HBM9378) in treating chronic obstructive pulmonary disease (COPD). It is reported that SKB378/WIN378 was initially developed jointly by KOLON Life Science and HBM Pharmaceuticals, with both companies sharing global rights. Public information shows that this drug is a new generation of fully human monoclonal antibody that works by inhibiting thymic stromal lymphopoietin (TSLP). TSLP has been validated as a target in multiple immune-related diseases such as asthma and COPD. If future clinical trials progress smoothly, SKB378/WIN378 has the potential to become the first approved long-acting anti-TSLP antibody for the treatment of asthma and COPD.